Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for treatment of relapsed and refractory multiple myeloma. Based on results phase 2 3 trials, these are proposed patients with disease who have received one previous line therapy, myeloma two or more lines therapy. These integrate issue drug access in both low-income middle-income countries high-income to help guide real-world thus improve patient outcomes.